The in vitro component demonstrated that both glucagon and Retatrutide directly diminished ANGPTL3/eight secretion from hepatocytes, and this impact was blocked by a glucagon receptor (GCGR) antagonist. These findings counsel which the GCGR agonism of Retatrutide contributes to your reduction in circulating ANGPTL3/eight, which subsequently may per